Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer

Journal of Nuclear Medicine

Volumn 39, Issue 1, 1998, Pages 4-8

  Crippa, Flavio ^a   Agresti, Roberto ^a   Seregni, Ettore ^a   Greco, Marco ^a   Pascali, Claudio ^a   Bogni, Anna ^a   Chiesa, Carlo ^a   De Sanctis, Vinicio ^a   Delledonne, Vincenzo ^a   Salvadori, Bruno ^a   Leutner, Monica ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Axillary metastasis; Breast cancer; Fluorine 18 fluorodeoxyglucose; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC;

AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031931680     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet 1991;339:1245-1248.
2. Danforth DN. The role of axillary lymph node dissection in the management of breast cancer. Princ Pract Oncol 1992;6:1-16.
3. Silverstein MJ, Gierson ED, Waisman JR. Axillary lymph node dissection for T1a breast carcinoma. Is it indicative? Cancer 1994;73:664-667.
4. Keramopoulos A, Tsionou C, Minaretsis D. Arm morbidity following treatment of breast cancer with totally axillary dissection: a multivariate approach. Oncology 1993;50:445-449.
5. 18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989; 13:1097-1098.
6. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770.
7. Nielson YT, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216:23-33.
8. Adler LP, Crowe JP, al Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with (F-18)-2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187:743-750.
9. Wahl RL, Helvie MA, Chang AE, Andersson I. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. J Nucl Med 1994;35:872-875.
10. Pietrzyk U, Scheidhauer K, Scharl A, Schicha H. Presurgical visualization of primary breast carcinoma with PET emission and transmission imaging. J Nucl Med 1995;36: 1882-1884.
11. 18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996;23:618-623.
12. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R, Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-2111.
13. Bassa P, Kim E, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-938.
14. 18F-FDG be considered as the best method? Int J Oncol 1996;8:693-699.
15. Hermanek P, Henson DE, Hutter RVP, eds. UICC complement: TNM classification of malignant tumors, 4th Ed., TNM supplement 1993: a commentary on uniform use. Berlin: Springer-Verlag, 1993.
16. 18F]FDG synthesis setup [Abstract]. Q J Nucl Med 1996;1: 48.
17. Schomburg A, Bender H, Reichel C, et al. Standardized uptake values of fluorine-18-fluorodeoxyglucose: the value of different normalization procedures. Eur J Nucl Med 1996;23:571-574.
18. 18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61-66.
19. Holle LH, Trampert L, Lung-Kurt S, et al. Investigations of breast tumors with fluorine-18-fluorodeoxyglucose and SPECT. J Nucl Med 1996;37:615-622.
20. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnosis of oncological patients. Eur J Nucl Med 1996;23:1409-1415.
21. Di Chiro G, Hatazawa J, Katz D, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987;164:521-526.
22. Alavi JB, Alavi A, Chawluk J. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074-1078.
23. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumor using PET. J Nucl Med 1991;32:1508-1512.
24. Reisser C, Haberkorn V, Strauss LG. The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. J Otolaryngol 1993;22:231-238.
25. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;35:1790-1796.
26. Greco M, Agresti R, Raselli R, Giovanazzi R, Veronesi U. Axillary dissection can be avoided in selected breast cancer patients: analysis of 401 cases. Anticancer Res 1996;16:3913-3918.